A potential approach to address these challenges involves targeting key proteins involved in BCR-ABL1-driven signaling pathways through ubiquitination and deubiquitylation regulation, offering a promising strategy for CML treatment. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.